Your browser doesn't support javascript.
loading
Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms.
Riddy, Darren M; Kammoun, Helene L; Murphy, Andrew J; Bosnyak-Gladovic, Sanja; De la Fuente Gonzalez, Rocio; Merlin, Jon; Ziemann, Mark; Fabb, Stewart; Pierce, Tracie L; Diepenhorst, Natalie; Rueda, Patricia; El-Osta, Assam; Gautier, Jean-Francois; Venteclef, Nicolas; Charman, William N; Christopoulos, Arthur; Sexton, Patrick M; Summers, Roger J; Febbraio, Mark A; Delerive, Philippe; Langmead, Christopher J.
Affiliation
  • Riddy DM; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia darren.riddy@monash.edu chris.langmead@monash.edu.
  • Kammoun HL; Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Murphy AJ; Haematopoiesis and Leukocyte Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
  • Bosnyak-Gladovic S; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • De la Fuente Gonzalez R; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Merlin J; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Ziemann M; Department of Diabetes, Monash University Central Clinical School, Melbourne, Victoria, Australia.
  • Fabb S; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Pierce TL; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Diepenhorst N; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Rueda P; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • El-Osta A; Department of Diabetes, Monash University Central Clinical School, Melbourne, Victoria, Australia.
  • Gautier JF; Inserm UMRS 1138, Département Diabète et Endocrinologie, Sorbonne Université, Paris, France.
  • Venteclef N; Inserm UMRS 1138, Département Diabète et Endocrinologie, Sorbonne Université, Paris, France.
  • Charman WN; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Christopoulos A; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Sexton PM; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Summers RJ; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Febbraio MA; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
  • Delerive P; Pôle d'Innovation Thérapeutique Métabolisme, Institut de Recherches Internationales Servier, Suresnes, France.
  • Langmead CJ; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia darren.riddy@monash.edu chris.langmead@monash.edu.
Article in En | MEDLINE | ID: mdl-34782333
ABSTRACT

INTRODUCTION:

A potential role for the orphan G protein-coupled receptor, GPR21, in linking immune cell infiltration into tissues and obesity-induced insulin resistance has been proposed, although limited studies in mice are complicated by non-selective deletion of Gpr21. RESEARCH DESIGN AND

METHODS:

We hypothesized that a Gpr21-selective knockout mouse model, coupled with type 2 diabetes patient samples, would clarify these issues and enable clear assessment of GPR21 as a potential therapeutic target.

RESULTS:

High-fat feeding studies in Gpr21-/- mice revealed improved glucose tolerance and modest changes in inflammatory gene expression. Gpr21-/- monocytes and intraperitoneal macrophages had selectively impaired chemotactic responses to monocyte chemoattractant protein (MCP)-1, despite unaltered expression of Ccr2. Further genotypic analysis revealed that chemotactic impairment was due to dysregulated monocyte polarization. Patient samples revealed elevated GPR21 expression in peripheral blood mononuclear cells in type 2 diabetes, which was correlated with both %HbA1c and fasting plasma glucose levels.

CONCLUSIONS:

Collectively, human and mouse data suggest that GPR21 influences both glucose homeostasis and MCP-1/CCL2-CCR2-driven monocyte migration. However, a Gpr21-/- bone marrow transplantation and high-fat feeding study in mice revealed no effect on glucose homeostasis, suggesting that there is no (or limited) overlap in the mechanism involved for monocyte-driven inflammation and glucose homeostasis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Diabetes Mellitus, Type 2 Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: BMJ Open Diabetes Res Care Year: 2021 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Insulin Resistance / Diabetes Mellitus, Type 2 Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: BMJ Open Diabetes Res Care Year: 2021 Type: Article